Press Releases

Placental Stem Cell Therapy Market Perspective with Professional Survey & Competitive Dynamics till 2022-2030

Share This Article

Placental Stem Cell Therapy Holds Promising Potentials in Treatment of Coronavirus

The placental mesenchymal stem cells therapy is gaining popularity as a potential solution for the treatment of severe COVID-19. The Institute of Cell Therapy is acquiring recognition for successfully curing COVID-19 patients with the help of placental stem cells lacking ACE-2 receptor, which hold promising potentials in the treatment of coronavirus pneumonia. As such, worldwide inoculation of coronavirus vaccines from India has caused a slowdown in research activities of the placental stem cell therapy market.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111547

Stakeholders in the placental stem cell therapy market are anticipated to continue their research for minimizing the impacts of future coronavirus-like outbreaks. They are boosting clinical trials to evaluate the efficacy of stem cells of different types for the treatment of COVID-19 in China.

Robust Analytics, Independent Measurement Systems Improve Consistency in Production

The placental stem cell therapy market stood at US$ 0.5 Bn in 2019 and is expected to cross a revenue of US$ 4.4 Bn by the end of 2030. However, manufacturing is a consistent challenge for stem cell companies across various industries such as for neurological disorders, hematologic malignancies, and congenital immunodeficiency disorders. Hence, companies are mastering batch-to-batch consistency of C to monitor results.

Companies in the placental stem cell therapy market are focusing on producing cells in a consistent and quality manner. ReNeuron – a developer of therapeutics from retina specific stem cells is increasing efforts to strike the right balance between science and art to maintain consistency in cell production for the treatment of retinitis pigmentosa (RP).

MSC-based Therapies Help in Treatment of Respiratory Diseases

Mesenchymal stromal cell (MSC)-based therapies are appearing as new therapeutic strategies for lung diseases. Idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), and acute respiratory distress syndrome (ARDS), among others, have triggered the demand for mesenchymal stromal cell-based therapies. MSCs are being publicized as multipotent cells with immune modulatory and regenerative properties. This explains why the placental stem cell therapy market is estimated to progress at an astonishing CAGR of 20% during the assessment period.

View full report@ https://qyresearchmedical.com/report/placental-stem-cell-therapy-market-application-hematologic-malignancies-and-disorders-congenital-immunodeficiency-disorders-metabolic-disorders-and-neurological-disorders-and-end-user-hospitals-specialty-cl-2020-2030/111547

The acute respiratory distress syndrome is emerging as an ideal target for the mesenchymal stromal cell-based therapy, since MSCs act as immunomodulatory cells via rapid-acting paracrine effects. Companies in the placental stem cell therapy market are increasing efforts to conduct pre-clinical studies that demonstrate the efficacy of MSCs for ARDS.

Hepatocytes Generated from Stem Cells Show Potential in Treatment of Congenital Metabolic Diseases

Since congenital metabolic diseases are associated with morbidity due to invasive procedures such as liver transplant, healthcare companies in the placental stem cell therapy market are capitalizing on this opportunity to offer regenerative cell therapies. Regenerative therapy using hepatocytes generated from stem cells has the potential to treat congenital metabolic diseases. This technique is gaining popularity as a less invasive cell replacement approach, suitable for the treatment of congenital metabolic diseases.

Embryonic stem cells are prone to risks of tumorigenicity and difficulties with cell expansion, owing to the number needed for the anticipated therapeutic effect. Human amniotic epithelial cells (hAECs) have caught the attention of companies in the placental stem cell therapy market to treat congenital metabolic diseases.

Combined Transplantation of Allogeneic Stem Cells Being Used to Cure Neurological Diseases

Cell therapy of neurological diseases is gaining momentum in the placental stem cell therapy market. Stem and progenitor cells are showing positive therapeutic results in animal models of neurological disorders within clinical trials. It has been found that each cell being tested has its advantages and drawbacks, owing to unique molecular mechanisms of action. This has led to the concept of combined transplantation of two or more cells.

The transplantation of various types of autologous or allogeneic stem/progenitor cells, including embryonic and induced pluripotent stem cells, has shown promising therapeutic outcomes in animal models of neurological diseases. Such findings are translating into revenue opportunities for companies in the placental stem cell therapy market.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111547/2900

Analysts’ Viewpoint

Mesenchymal stem cells are emerging as powerful immunomodulators that are playing a key role in advancements made for the treatment of severe COVID-19 patients. MSC-based therapies hold future prospects for companies in the placental stem cell therapy market to create therapeutics for bronchopulmonary dysplasia (BPD) in infants born prematurely. MSCs have proven paracrine activity, which helps migrate toward inflamed sites and improves outcomes in patients suffering from neurological disorders. Ethical issues and immune mediated rejection of transplanted cells are posing as hurdles in the treatment of congenital metabolic diseases. Hence, companies should increase the production of human amniotic epithelial cells (hAECs) that are emerging as an alternative to hepatocyte transplantation (HT) for patients suffering from congenital metabolic diseases.

Placental Stem Cell Therapy Market: Overview

The global placental stem cell therapy market for the historical period 2018–2019 and the forecast period of 2020–2030, prominence in treatment of age-related disorders/diseases and increase in awareness about stem cell therapies are projected to drive the global placental stem cell therapy market in the near future

According to the report, the global placental stem cell therapy market was valued at US$ 0.5 Bn in 2019. It is anticipated to expand at a CAGR of 20% from 2020 to 2030.

Regenerative Ability to Develop into Other Types of Cells to Drive Global Market

Placental therapy is being used to promote recovery from diseases and tissue regeneration since the early 1900s. Since then, placental stem cell therapy has been applied in various clinical applications, as it has exhibited remarkable therapeutic attributes, ranging from anti-oxidant, anti-microbial, anti-inflammatory, pain reduction, hair growth promotion, health improvement, and cellular proliferation to tissue regeneration and wound healing properties in vivo. This review further summarizes historical aspects, cellular mechanism, nutrient content, and therapeutics properties of the placenta.

Placental stem cells offer the potential to treat rare diseases or conditions for which few treatments exist. Sometimes called the body’s “master cells,” these cells can develop into blood, brain, bones, and all of the body’s organs.

These have the potential to repair, restore, replace, and regenerate cells, and could possibly be used to treat several medical conditions and diseases

Placental stem cell therapy is quite useful for the cure of diseases such as Alzheimer’s disease

According to the WHO, worldwide, around 50 million people have dementia and nearly 10 million new cases are recorded every year. Alzheimer’s disease is a highly common form of dementia and contributes to 60% to 70% of cases.

Ease of Procurement

Placenta is a vascular organ with a known duration of life, and is only developed during the occurrence of pregnancy. It attaches to the uterine wall and the umbilical cord, which connects between the mother and the fetus, thereby supporting the growth and development of the fetus.

Placenta plays an important role in transfer of gases, nutrients, and removal of waste products during pregnancy, which is vital for the sustenance of the fetus

Placenta stem cells also provide additional benefit as compared to that offered by other tissues. These cells are easy to procure, with no harm to the mother or the baby. There are also no ethical issues associated with obtaining placenta, as it is considered a biological waste after birth.

Placenta has high cell yield and is less exposed to infection, as it comes from an infection-naïve environment. This makes rendering any disease transmission less likely. This factor is considered a major driver of the placental stem cell therapy market.

Rise in the number of storage banks and the awareness among people are key factors boosting the adoption of placental stem cell therapy

Increase in Awareness about Stem Cell Therapies

Several programs have been conducted to spread awareness about stem cell therapies and educate about the ethical aspects in the field

Every October, the global stem cell community comes together to promote appreciation and understanding of stem cell research on Stem Cell Awareness Day

In emerging countries, such as India, awareness and acceptance for stem cell therapy are increasing rapidly

In 2016, NeuroGen Brain and Spine Institute conducted awareness programs about stem cell therapy in Karnataka (India) and other neighboring states. Thus far, the institute has successfully treated over 800 patients.

Competition Landscape

This report profiles major players operating in the global placental stem cell therapy market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global placental stem cell therapy market is moderately fragmented, with the presence of a large number of leading players in the global market and several small players in regional markets. Top players hold a major share of the global placental stem cell therapy market.

Prominent players operating in the global placental stem cell therapy market include

  • Lifebank Stem Cell Banking
  • Celularity, Inc.
  • Americord Registry
  • ReeLabs Pvt. Ltd.
  • Pluristem Therapeutics, Inc.
  • Mesoblast Limited
  • ReNeuron Group plc
  • Athersys, Inc.

The report on the global placental stem cell therapy market discusses individual strategies, followed by company profiles of providers of stem cell therapy. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global placental stem cell therapy market.

Key Questions Answered in Placental Stem Cell Therapy Market Report

  • What is the sales/revenue generated by the placental stem cell therapy market across all regions during the forecast period?
  • What are the opportunities in the global placental stem cell therapy market?
  • What are major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which drug class segment is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Placental Stem Cell Therapy Market – Segmentation

Application

  • Hematologic Malignancies and Disorders
  • Congenital Immunodeficiency Disorders
  • Metabolic Disorders
  • Neurological Disorders

End User

  • Hospitals & Specialty Clinics
  • Clinical Research Organizations
  • Research Institutes & Academies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America

TABLE OF CONTENT

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Placental Stem Cell Therapy Market

4. Market Overview

4.1. Introduction

4.1.1. Application Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Placental Stem Cell Therapy Market Analysis and Forecast, 2018–2030

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Supply Chain Analysis

5.1.1. Placental Stem Cells Collection & Isolation

5.1.2. Cell processing & Cryo-preservation

5.1.3. Cell Differentiation

5.1.4. Cell Culture and Expansion

5.2. Pipeline Analysis

5.3. Regulatory Scenario, by Region/globally

5.4. Reimbursement Scenario, by Region/globally

5.5. Pricing Analysis, 2019

5.6. COVID-19 Pandemic Impact on Industry

6. Global Placental Stem Cell Therapy Market Analysis and Forecast, by Application

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Global Placental Stem Cell Therapy Market Value Forecast, by Application, 2018–2030

6.3.1. Hematologic Malignancies and Disorders

6.3.2. Congenital Immunodeficiency Disorders

6.3.3. Metabolic Disorders

6.3.4. Neurological Disorders

6.3.5. Others

6.4. Global Placental Stem Cell Therapy Market Attractiveness Analysis, by Application

7. Global Placental Stem Cell Therapy Market Analysis and Forecast, by End-user

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Global Placental Stem Cell Therapy Market Value Forecast, by End-user, 2018–2030

7.3.1. Hospitals & Specialty Clinics

7.3.2. Clinical Research Organizations

7.3.3. Research Institutes & Academies

7.4. Global Placental Stem Cell Therapy Market Attractiveness Analysis, by End-user

8. Global Placental Stem Cell Therapy Market Analysis and Forecast, by Region

8.1. Key Findings

8.2. Global Placental Stem Cell Therapy Market Value Forecast, by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Global Placental Stem Cell Therapy Market Attractiveness Analysis, by Country/Region

9. North America Placental Stem Cell Therapy Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. North America Placental Stem Cell Therapy Market Value Forecast, by Application, 2018–2030

9.2.1. Hematologic Malignancies and Disorders

9.2.2. Congenital Immunodeficiency Disorders

9.2.3. Metabolic Disorders

9.2.4. Neurological Disorders

9.2.5. Others

9.3. North America Placental Stem Cell Therapy Market Value Forecast, by End-user, 2018–2030

9.3.1. Hospitals & Specialty Clinics

9.3.2. Clinical Research Organizations

9.3.3. Research Institutes & Academies

9.4. North America Placental Stem Cell Therapy Market Value Forecast, by Country, 2018–2030

9.4.1. U.S.

9.4.2. Canada

9.5. North America Placental Stem Cell Therapy Market Attractiveness Analysis

9.5.1. By Application

9.5.2. By End-user

9.5.3. By Country

10. Europe Placental Stem Cell Therapy Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Europe Placental Stem Cell Therapy Market Value Forecast, by Application, 2018–2030

10.2.1. Hematologic Malignancies and Disorders

10.2.2. Congenital Immunodeficiency Disorders

10.2.3. Metabolic Disorders

10.2.4. Neurological Disorders

10.2.5. Others

10.3. Europe Placental Stem Cell Therapy Market Value Forecast, by End-user, 2018–2030

10.3.1. Hospitals & Specialty Clinics

10.3.2. Clinical Research Organizations

10.3.3. Research Institutes & Academies

10.4. Europe Placental Stem Cell Therapy Market Value Forecast, by Country/Sub-region, 2018–2030

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Rest of Europe

10.5. Europe Placental Stem Cell Therapy Market Attractiveness Analysis

10.5.1. By Application

10.5.2. By End-user

10.5.3. By Country/Sub-region

11. Asia Pacific Placental Stem Cell Therapy Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Asia Pacific Placental Stem Cell Therapy Market Value Forecast, by Application, 2018–2030

11.2.1. Hematologic Malignancies and Disorders

11.2.2. Congenital Immunodeficiency Disorders

11.2.3. Metabolic Disorders

11.2.4. Neurological Disorders

11.2.5. Others

11.3. Asia Pacific Placental Stem Cell Therapy Market Value Forecast, by End-user, 2018–2030

11.3.1. Hospitals & Specialty Clinics

11.3.2. Clinical Research Organizations

11.3.3. Research Institutes & Academies

11.4. Asia Pacific Placental Stem Cell Therapy Market Value Forecast, by Country/Sub-region, 2018–2030

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Asia Pacific Placental Stem Cell Therapy Market Attractiveness Analysis

11.5.1. By Application

11.5.2. By End-user

11.5.3. By Country/Sub-region

12. Latin America Placental Stem Cell Therapy Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Latin America Placental Stem Cell Therapy Market Value Forecast, by Application, 2018–2030

12.2.1. Hematologic Malignancies and Disorders

12.2.2. Congenital Immunodeficiency Disorders

12.2.3. Metabolic Disorders

12.2.4. Neurological Disorders

12.2.5. Others

12.3. Latin America Placental Stem Cell Therapy Market Value Forecast, by End-user, 2018–2030

12.3.1. Hospitals & Specialty Clinics

12.3.2. Clinical Research Organizations

12.3.3. Research Institutes & Academies

12.4. Latin America Placental Stem Cell Therapy Market Value Forecast, by Country/Sub-region, 2018–2030

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Latin America Placental Stem Cell Therapy Market Attractiveness Analysis

12.5.1. By Application

12.5.2. By End-user

12.5.3. By Country//Sub-region

13. Middle East & Africa Placental Stem Cell Therapy Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Middle East & Africa Placental Stem Cell Therapy Market Value Forecast, by Application, 2018–2030

13.2.1. Hematologic Malignancies and Disorders

13.2.2. Congenital Immunodeficiency Disorders

13.2.3. Metabolic Disorders

13.2.4. Neurological Disorders

13.2.5. Others

13.3. Middle East & Africa Placental Stem Cell Therapy Market Value Forecast, by End-user, 2018–2030

13.3.1. Hospitals & Specialty Clinics

13.3.2. Clinical Research Organizations

13.3.3. Research Institutes & Academies

13.4. Middle East & Africa Placental Stem Cell Therapy Market Value Forecast, by Country/Sub-region, 2018–2030

13.4.1. GCC Countries

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Middle East & Africa Placental Stem Cell Therapy Market Attractiveness Analysis

13.5.1. By Application

13.5.2. By End-user

13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player – Competition Matrix (by tier and size of companies)

14.2. Market Share Analysis, by Company, 2019

14.3. Company Profiles

14.3.1. Lifebank Stem Cell Banking

14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)

14.3.1.2. Product Portfolio

14.3.1.3. SWOT Analysis

14.3.1.4. Strategic Overview

14.3.2. Celularity, Inc.

14.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)

14.3.2.2. Product Portfolio

14.3.2.3. SWOT Analysis

14.3.2.4. Strategic Overview

14.3.3. Americord Registry

14.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)

14.3.3.2. Product Portfolio

14.3.3.3. SWOT Analysis

14.3.3.4. Strategic Overview

14.3.4. ReeLabs Pvt. Ltd.

14.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)

14.3.4.2. Product Portfolio

14.3.4.3. SWOT Analysis

14.3.4.4. Strategic Overview

14.3.5. Pluristem Therapeutics, Inc.

14.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)

14.3.5.2. Product Portfolio

14.3.5.3. SWOT Analysis

14.3.5.4. Strategic Overview

14.3.6. Mesoblast Limited

14.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)

14.3.6.2. Product Portfolio

14.3.6.3. SWOT Analysis

14.3.6.4. Strategic Overview

14.3.7. ReNeuron Group plc

14.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)

14.3.7.2. Product Portfolio

14.3.7.3. SWOT Analysis

14.3.7.4. Strategic Overview

14.3.8. Athersys, Inc.

14.3.8.1 Company Overview (HQ, Business Segments, Employee Strength)

14.3.8.2. Product Portfolio

14.3.8.3. SWOT Analysis

14.3.8.4. Strategic Overview

14.3.9. Other Prominent Key Players

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111547/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Related Articles

Back to top button